company background image
SOLARA logo

Solara Active Pharma Sciences NSEI:SOLARA Stock Report

Last Price

₹565.25

Market Cap

₹27.1b

7D

-9.1%

1Y

48.0%

Updated

17 Jul, 2024

Data

Company Financials +

Solara Active Pharma Sciences Limited

NSEI:SOLARA Stock Report

Market Cap: ₹27.1b

SOLARA Stock Overview

Manufactures, produces, processes, formulates, sells, imports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India.

SOLARA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Solara Active Pharma Sciences Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Solara Active Pharma Sciences
Historical stock prices
Current Share Price₹565.25
52 Week High₹639.70
52 Week Low₹286.00
Beta1.05
11 Month Change29.78%
3 Month Change19.30%
1 Year Change47.97%
33 Year Change-66.08%
5 Year Change53.58%
Change since IPO124.53%

Recent News & Updates

Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

Jun 05
Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

Recent updates

Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

Jun 05
Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

May 11
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Apr 19
Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Mar 13
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Feb 23
Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Jan 04
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

May 12
Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Nov 08
Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Sep 30
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Aug 03
Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Jun 19
Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Dec 21
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

With EPS Growth And More, Solara Active Pharma Sciences (NSE:SOLARA) Is Interesting

Oct 28
With EPS Growth And More, Solara Active Pharma Sciences (NSE:SOLARA) Is Interesting

Shareholder Returns

SOLARAIN PharmaceuticalsIN Market
7D-9.1%0.8%0.8%
1Y48.0%51.4%45.4%

Return vs Industry: SOLARA underperformed the Indian Pharmaceuticals industry which returned 51.4% over the past year.

Return vs Market: SOLARA exceeded the Indian Market which returned 45.4% over the past year.

Price Volatility

Is SOLARA's price volatile compared to industry and market?
SOLARA volatility
SOLARA Average Weekly Movement10.0%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.7%
10% least volatile stocks in IN Market4.2%

Stable Share Price: SOLARA's share price has been volatile over the past 3 months.

Volatility Over Time: SOLARA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
20172,361Poorvank Purohitwww.solara.co.in

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, loop diuretic, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, topical anti-infectives, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, nucleoside inhibitor, aprepitant, NSAIDs, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support.

Solara Active Pharma Sciences Limited Fundamentals Summary

How do Solara Active Pharma Sciences's earnings and revenue compare to its market cap?
SOLARA fundamental statistics
Market cap₹27.13b
Earnings (TTM)-₹5.67b
Revenue (TTM)₹12.89b

2.1x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SOLARA income statement (TTM)
Revenue₹12.89b
Cost of Revenue₹8.05b
Gross Profit₹4.84b
Other Expenses₹10.51b
Earnings-₹5.67b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 22, 2024

Earnings per share (EPS)-118.20
Gross Margin37.54%
Net Profit Margin-44.02%
Debt/Equity Ratio106.7%

How did SOLARA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.